Conditions: Skin Cancer; Melanoma (Skin Cancer); Basal Cell Carcinoma of Skin; Basal Cell Carcinoma of Skin, Site Unspecified; Cutaneous Squamous Cell Carcinoma (CSCC); Merkel Cell Carcinoma of Skin
Interventions: Other: Blood draw for the laboratory assessment
Sponsors: University of Wisconsin, Madison; National Center for Advancing Translational Sciences (NCATS)
Not yet recruiting
Feeds
32878 items (32878 unread) in 74 feeds
Acinar Cell Carcinoma
(522 unread)
Acinic Cell Carcinoma
(306 unread)
Adenoid Cystic Carcinoma
(550 unread)
Adrenal Gland Cancer
(2410 unread)
Ampulla Of Vater
(469 unread)
Anal Cancer
(2709 unread)
Angiosarcoma
(990 unread)
Appendix Cancer
(684 unread)
Bile Duct Cancer
(4355 unread)
Brain and CNS
(6120 unread)
Carcinoid
(887 unread)
Endocrine/Neuroendocrine
(5825 unread)
Gall Bladder Cancer
(1132 unread)
Hemangioendothelioma
(1176 unread)
Hepatoblastoma
(770 unread)
Pancreas
(563 unread)
Phyllodes
(384 unread)
PMP and Mucinous Tumors
(477 unread)
Rhabdomyosarcoma
(1118 unread)
Sarcoma
(1431 unread)
Trial - Merkel Cell Cancer (71 unread)
-
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
Posted: September 23rd, 2024, 11:00pm UTC
-
Personalised Immunotherapy Platform (PIP-PREDICT)
Posted: August 2nd, 2024, 11:00pm UTC
Conditions: Melanoma; Cutaneous Squamous Cell Carcinoma; Basal Cell Carcinoma; Merkel Cell Carcinoma; Solid Tumor
Interventions: Other: Predictive model
Sponsors: Melanoma Institute Australia
Recruiting -
Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma
Posted: June 7th, 2024, 11:00pm UTC
Conditions: Merkel Cell Carcinoma
Interventions: Other: Blood Test
Sponsors: University Hospital, Montpellier
Not yet recruiting -
A Study of VET3-TGI in Patients With Solid Tumors
Posted: June 6th, 2024, 11:00pm UTC
Conditions: Solid Tumor, Adult; Microsatellite Stable Colorectal Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Kidney Cancer; Renal Cell Carcinoma; Melanoma Stage IV; Merkel Cell Carcinoma of Skin; Mesothelioma; Non-small Cell Lung Cancer
Interventions: Drug: VET3-TGI; Drug: Pembrolizumab
Sponsors: KaliVir Immunotherapeutics
Recruiting -
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Posted: January 25th, 2024, 1:00am UTC
Conditions: Cutaneous Melanoma; Merkel Cell Carcinoma; Skin Squamous Cell Carcinoma
Interventions: Drug: Eutectic Mixture of Local Anesthetics; Drug: Placebo Administration; Other: Questionnaire Administration
Sponsors: Ohio State University Comprehensive Cancer Center
Recruiting -
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Posted: November 30th, 2023, 1:00am UTC
Conditions: Merkel Cell Carcinoma
Interventions: Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
Sponsors: Melanoma Institute Australia; Bristol-Myers Squibb
Recruiting -
A Study of CRD3874-SI in People With Solid Tumors
Posted: September 1st, 2023, 11:00pm UTC
Conditions: Sarcoma; Merkel Cell Carcinoma
Interventions: Drug: CRD3874
Sponsors: Memorial Sloan Kettering Cancer Center; Curadev Pharma
Recruiting -
Intratumoral PH-762 for Cutaneous Carcinoma
Posted: August 28th, 2023, 11:00pm UTC
Conditions: Squamous Cell Carcinoma of the Skin; Malignant Melanoma of Skin; Merkel Cell Carcinoma of Skin
Interventions: Drug: PH-762
Sponsors: Phio Pharmaceuticals Inc.; Prosoft Clinical
Recruiting -
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
Posted: August 24th, 2023, 11:00pm UTC
Conditions: Cutaneous Melanoma; Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma
Interventions: Other: Exercise Test
Sponsors: AdventHealth Translational Research Institute
Recruiting -
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Posted: June 9th, 2023, 11:00pm UTC
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Metastatic Basal Cell Carcinoma; Metastatic Carcinoma in the Skin; Metastatic Melanoma; Metastatic Merkel Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Unresectable Basal Cell Carcinoma; Unresectable Melanoma; Unresectable Merkel Cell Carcinoma; Unresectable Skin Squamous Cell Carcinoma
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Ipilimumab; Procedure: Kidney Biopsy; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab; Drug: Prednisone; Drug: Sirolimus
Sponsors: National Cancer Institute (NCI)
Recruiting -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Posted: May 15th, 2023, 11:00pm UTC
Conditions: Cutaneous Squamous Cell Carcinoma; SCC - Squamous Cell Carcinoma; Basal Cell Carcinoma; BCC; BCC - Basal Cell Carcinoma; Melanoma; Merkel Cell Carcinoma; Sebaceous Carcinoma; Extramammary Paget Disease; Kaposi Sarcoma; Head and Neck Squamous Cell Carcinoma; HNSCC; Adnexal Carcinoma; Angiosarcoma; Cutaneous Neoplasm; Advanced Cancer; Metastatic Cancer; Refractory Cancer; Solid Tumor
Interventions: Biological: MQ719; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center
Active, not recruiting -
Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers
Posted: April 4th, 2023, 11:00pm UTC
Conditions: Ocular Sebaceous Carcinoma; Ocular Basal Cell Carcinoma; Ocular Surface Squamous Neoplasia; Merkel Cell Carcinoma, Unspecified; Porocarcinoma; Conjunctival Melanoma
Interventions: Procedure: Sentinel Lymph Node Biopsy
Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting -
Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
Posted: November 8th, 2022, 1:00am UTC
Conditions: Basal Cell Carcinoma; Tomography, Optical Coherence
Interventions: Other: Dynamic full-field optical coherence tomography analysis of skin biopsy or resection
Sponsors: Centre Hospitalier William Morey - Chalon sur Saône
Completed -
Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery
Posted: October 26th, 2022, 11:00pm UTC
Conditions: Merkel Cell Carcinoma
Interventions: Drug: Retifanlimab; Drug: Cisplatin; Drug: Etoposide
Sponsors: Gruppo Oncologico del Nord-Ovest
Recruiting -
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Posted: October 24th, 2022, 11:00pm UTC
Conditions: Advanced Solid Tumors; Genital Neoplasm, Female; Urogenital Neoplasms; Lung Neoplasm; Neoplasms by Site; Papillomavirus Infection; Epstein-Barr Virus Infections; Carcinoma; Neoplasms; Vulvar Neoplasms; Vulvar Diseases; Abdominal Neoplasm
Interventions: Drug: STAR0602
Sponsors: Marengo Therapeutics, Inc.
Recruiting -
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Posted: October 18th, 2022, 11:00pm UTC
Conditions: Merkel Cell Carcinoma
Interventions: Drug: Pembrolizumab; Drug: Lutetium Lu 177 dotatate
Sponsors: Weill Medical College of Cornell University
Suspended -
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Posted: August 10th, 2022, 11:00pm UTC
Conditions: Merkel Cell Carcinoma
Interventions: Drug: Pembrolizumab
Sponsors: Abramson Cancer Center at Penn Medicine; Merck Sharp & Dohme LLC
Recruiting -
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
Posted: May 3rd, 2022, 11:00pm UTC
Conditions: Cutaneous Melanoma; Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma
Interventions: Other: Exercise; Drug: Checkpoint Blockade, Immune
Sponsors: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Posted: March 8th, 2022, 1:00am UTC
Conditions: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Merkel Cell Carcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Cervical Carcinoma; Locally Advanced Endometrial Carcinoma; Locally Advanced Gastric Adenocarcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Locally Advanced Head and Neck Squamous Cell Carcinoma; Locally Advanced Hepatocellular Carcinoma; Locally Advanced Lung Non-Small Cell Carcinoma; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Locally Advanced Merkel Cell Carcinoma; Locally Advanced Renal Cell Carcinoma; Locally Advanced Skin Squamous Cell Carcinoma; Locally Advanced Triple-Negative Breast Carcinoma; Locally Advanced Unresectable Breast Carcinoma; Locally Advanced Unresectable Cervical Carcinoma; Locally Advanced Unresectable Gastric Adenocarcinoma; Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma; Locally Advanced Unresectable Renal Cell Carcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Cervical Carcinoma; Metastatic Endometrial Carcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Merkel Cell Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Metastatic Urothelial Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IV Merkel Cell Carcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Skin Squamous Cell Carcinoma; Stage III Cervical Cancer AJCC v8; Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Cervical Cancer AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIB Cervical Cancer AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Cervical Carcinoma; Unresectable Endometrial Carcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma; Unresectable Head and Neck Squamous Cell Carcinoma; Unresectable Hepatocellular Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma; Unresectable Merkel Cell Carcinoma; Unresectable Renal Cell Carcinoma; Unresectable Skin Squamous Cell Carcinoma; Unresectable Triple-Negative Breast Carcinoma; Unresectable Urothelial Carcinoma
Interventions: Drug: Cyclophosphamide; Biological: Neoantigen Peptide Vaccine; Biological: Pembrolizumab; Biological: Sargramostim
Sponsors: Mayo Clinic
Recruiting -
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Posted: March 4th, 2022, 1:00am UTC
Conditions: Advanced Solid Tumor; Metastatic Cancer
Interventions: Drug: AU-007; Drug: Aldesleukin; Drug: Avelumab
Sponsors: Aulos Bioscience, Inc.
Recruiting -
Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC
Posted: February 23rd, 2022, 1:00am UTC
Conditions: Merkel Cell Carcinoma
Interventions: Radiation: Radiotherapy; Procedure: Surgery
Sponsors: University of Birmingham; Efficacy and Mechanism Evaluation (EME) Programme
Completed -
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
Posted: November 15th, 2021, 1:00am UTC
Conditions: Hepatocellular Carcinoma; Squamous Cell Carcinoma of the Lung; Merkel Cell Carcinoma; Myxoid/Round Cell Liposarcoma
Interventions: Biological: CAR-GPC3 T Cells
Sponsors: Sotio Biotech Inc.; SOTIO Biotech AG; SOTIO Biotech a.s.
Recruiting -
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Posted: October 29th, 2021, 11:00pm UTC
Conditions: Merkel Cell Carcinoma
Interventions: Drug: Radiation therapy
Sponsors: M.D. Anderson Cancer Center
Recruiting -
A Beta-only IL-2 ImmunoTherapY Study
Posted: October 21st, 2021, 11:00pm UTC
Conditions: Advanced Solid Tumor; Unresectable Solid Tumor; Clear Cell Renal Cell Carcinoma; Triple Negative Breast Cancer; Non-Small Cell Lung Cancer Squamous; Non-Small Cell Lung Cancer Non-squamous; Colorectal Cancer (MSI-H); Gastric Cancer; Cervical Cancer; Basal Cell Carcinoma; Bladder Cancer; Merkel Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Cutaneous Squamous Cell Carcinoma; Pleural Mesothelioma; Esophageal Cancer; Endometrial Carcinoma; Solid Tumor; Solid Tumor, Adult; MSI-H Solid Malignant Tumor; Cancer With A High Tumor Mutational Burden; Epithelial Ovarian Carcinoma; Primary Peritoneal Cancer; Gastroesophageal Junction (GEJ) Cancer; Acral Melanoma; Mucosal Melanoma; Cutaneous Melanoma; DMMR Solid Malignant Tumor; Fallopian Tube Cancer; Ovarian Cancer; MSI-H Cancer; DMMR Cancer; Pancreas Adenocarcinoma (MSI-H); Skin Cancer
Interventions: Drug: MDNA11; Drug: Pembrolizumab (KEYTRUDA®)
Sponsors: Medicenna Therapeutics, Inc.; Merck Sharp & Dohme LLC
Recruiting -
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Posted: October 14th, 2021, 11:00pm UTC
Conditions: Lung Cancer Metastatic; Renal Cell Carcinoma; Head and Neck Cancer; Triple Negative Breast Cancer; Merkel Cell Carcinoma; Hepatocellular Carcinoma; Melanoma; Urothelial Carcinoma; Colorectal Carcinoma With Microsatellite Instability; Esophageal Squamous Cell Carcinoma; Endometrial Carcinoma; Cervical Cancer; Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma; Basal Cell Carcinoma; Squamous Skin Carcinoma
Interventions: Drug: Reduced dose intensity of IO
Sponsors: UNICANCER
Recruiting -
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
Posted: August 19th, 2021, 11:00pm UTC
Conditions: Melanoma; Merkel Cell Carcinoma, Unspecified; Renal Cell Carcinoma; Non Small Cell Lung Cancer
Interventions: Biological: zirconium Zr 89 crefmirlimab berdoxam
Sponsors: ImaginAb, Inc.
Active, not recruiting -
GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
Posted: July 27th, 2021, 11:00pm UTC
Conditions: Advanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Renal Cell Carcinoma; Urinary Bladder Cancer; Melanoma; Sarcoma; Microsatellite Stable Colorectal Carcinoma; Merkel Cell Carcinoma; Esophageal Squamous Cell Carcinoma; Cervical Cancer; Vaginal Cancer; Vulvar Cancer
Interventions: Drug: GI-101; Drug: Pembrolizumab (KEYTRUDA®); Drug: Lenvatinib; Radiation: Local Radiotherapy; Drug: GI-101A
Sponsors: GI Innovation, Inc.; Merck Sharp & Dohme LLC
Recruiting -
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
Posted: July 23rd, 2021, 11:00pm UTC
Conditions: Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma
Interventions: Drug: Cemiplimab-Rwlc
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Regeneron Pharmaceuticals; Sanofi-Synthelabo
Recruiting -
A Trial to Find Out if Vidutolimod Together With Cemiplimab is Safe and if it Works in Adult Participants With Advanced Cancer or Metastatic Cancer
Posted: June 7th, 2021, 11:00pm UTC
Conditions: Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Basal Cell Carcinoma; Triple Negative Breast Cancer; Non-Small Cell Lung Cancer; Oropharynx Squamous Cell Carcinoma
Interventions: Drug: vidutolimod; Drug: cemiplimab
Sponsors: Regeneron Pharmaceuticals
Active, not recruiting -
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Posted: May 26th, 2021, 11:00pm UTC
Conditions: Viral Associated Malignancies; Kaposi Sarcoma; EBV/KSHV-associated Lymphomas
Interventions: Drug: Pomalidomide; Drug: Nivolumab
Sponsors: National Cancer Institute (NCI)
Recruiting -
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
Posted: May 26th, 2021, 11:00pm UTC
Conditions: Advanced Bladder Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Merkel Cell Carcinoma; Advanced Renal Cell Carcinoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Merkel Cell Carcinoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage III Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage IV Merkel Cell Carcinoma AJCC v8; Stage III Bladder Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Bladder Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IVA Bladder Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Bladder Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Biological: Atezolizumab; Drug: Avelumab; Biological: Durvalumab; Biological: Nivolumab; Biological: Pembrolizumab; Drug: Plinabulin; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center
Recruiting -
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
Posted: May 3rd, 2021, 11:00pm UTC
Conditions: Merkel Cell Carcinoma; Neuroendocrine Carcinoma of the Skin; Trabecular Carcinoma of the Skin
Interventions: Drug: Lenvatinib Oral Product; Drug: Pembrolizumab
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme LLC
Recruiting -
IFx-Hu2.0 Expanded Access Program
Posted: April 21st, 2021, 11:00pm UTC
Conditions: Cutaneous Melanoma, Stage III; Cutaneous Melanoma, Stage IV; Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma
Interventions: Biological: IFx-Hu2.0
Sponsors: TuHURA Biosciences, Inc.
Available -
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
Posted: March 10th, 2021, 1:00am UTC
Conditions: Merkel Cell Carcinoma
Interventions: Drug: Avelumab; Radiation: Comprehensive Ablative Radiation Therapy
Sponsors: Memorial Sloan Kettering Cancer Center; EMD Serono
Recruiting -
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Posted: January 26th, 2021, 1:00am UTC
Conditions: Metastatic Cancer; Soft Tissue Sarcoma; Merkel Cell Carcinoma; Melanoma; Triple Negative Breast Cancer; Non Small Cell Lung Cancer
Interventions: Biological: BT-001; Drug: Pembrolizumab [KEYTRUDA®]
Sponsors: Transgene; BioInvent International AB; Merck Sharp & Dohme LLC
Recruiting -
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Posted: July 7th, 2020, 11:00pm UTC
Conditions: Neoplasm Metastasis
Interventions: Drug: PF-07265807; Drug: Sasanlimab; Drug: Axitinib
Sponsors: Pfizer
Active, not recruiting -
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1
Posted: May 19th, 2020, 11:00pm UTC
Conditions: Merkel Cell Carcinoma
Interventions: Drug: domatinostat in combination with avelumab
Sponsors: 4SC AG
Completed -
A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies
Posted: April 16th, 2020, 11:00pm UTC
Conditions: Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma; Basal Cell Carcinoma; Melanoma
Interventions: Biological: RP1, intra-tumoral injection, oncolytic virus
Sponsors: Replimune Inc.
Recruiting -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Posted: February 17th, 2020, 1:00am UTC
Conditions: Advanced Solid Tumors; MSI-H/dMMR Tumors; Cutaneous Squamous Cell Carcinoma; Urothelial Carcinoma, HCC; Cervical Cancer; Esophageal Squamous Cell Carcinoma; Merkel Cell Carcinoma; Small-cell Lung Cancer; Mesothelioma; PD-L1 Amplified Tumor (9p24.1); Nasopharyngeal Carcinoma; Cyclin-dependent Kinase 12 Mutated Tumors; Basal Cell Carcinoma (Unresectable or Metastatic); Sarcomatoid Renal Cell Carcinoma; Clear Cell Ovarian or Endometrial Carcinoma; Anal Carcinoma; Squamous Cell Penile Carcinoma; DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)
Interventions: Drug: INCB099318
Sponsors: Incyte Corporation
Active, not recruiting -
Targeted Therapy and Avelumab in Merkel Cell Carcinoma
Posted: February 10th, 2020, 1:00am UTC
Conditions: Metastatic Merkel Cell Carcinoma
Interventions: Drug: Avelumab; Radiation: External Beam Radiation Therapy (EBRT); Radiation: Lutetium-177 (177Lu)-DOTATATE
Sponsors: Melanoma and Skin Cancer Trials Limited
Recruiting -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Posted: January 27th, 2020, 1:00am UTC
Conditions: Advanced Solid Tumor; MSI-H/dMMR Tumors; Cutaneous Squamous Cell Carcinoma; Urothelial Carcinoma; Cervical Cancer; HepatoCellular Carcinoma; Esophageal Squamous Cell Carcinoma; Merkel Cell Carcinoma; Small-cell Lung Cancer; Mesothelioma; PD-L1 Amplified Tumor (9p24.1); Nasopharyngeal Carcinoma
Interventions: Drug: INCB099280
Sponsors: Incyte Corporation
Active, not recruiting -
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
Posted: January 21st, 2020, 1:00am UTC
Conditions: Thyroid Cancer; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Melanoma; Merkel Cell Carcinoma; Skin Squamous Cell Carcinoma; Microsatellite Instability High; Triple Negative Breast Cancer; Mesothelioma; Thymic Cancer; Cervical Cancer; Biliary Tract Cancer; Hepatocellular Carcinoma; Ovarian Cancer; Gastric Cancer; Head and Neck Squamous Cell Carcinoma; Anal Cancer
Interventions: Drug: Nanrilkefusp alfa; Drug: Pembrolizumab
Sponsors: SOTIO Biotech AG; SOTIO Biotech a.s.
Active, not recruiting -
LITT and Pembrolizumab in Recurrent Brain Metastasis
Posted: December 5th, 2019, 1:00am UTC
Conditions: Melanoma; Non-small Cell Lung Carcinoma (NSCLC); Renal Cell Carcinoma (RCC); Small-cell Lung Cancer; Head and Neck Squamous Cell Cancer; Classical Hodgkin Lymphoma; Primary Mediastinal Large B-Cell Lymphoma; Urothelial Carcinoma; Microsatellite Instability-High Cancer; Gastric Cancer; Esophageal Cancer; Cervical Cancer; Hepatocellular Carcinoma; Merkel Cell Carcinoma; Brain Metastases, Adult
Interventions: Combination Product: LITT + Pembrolizumab
Sponsors: University of Florida; Monteris Medical
Terminated -
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers
Posted: November 12th, 2019, 1:00am UTC
Conditions: Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Non-Melanoma Skin Cancers
Interventions: Biological: IFx-Hu2.0
Sponsors: TuHURA Biosciences, Inc.; H. Lee Moffitt Cancer Center and Research Institute; University of Southern California; Dana-Farber Cancer Institute; Huntsman Cancer Institute
Completed -
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Posted: November 8th, 2019, 1:00am UTC
Conditions: Advanced Solid Tumors; NSCLC; Bladder Cancer; HNSCC; Renal Cancer; Melanoma; Anal Cancer; Colorectal Cancer; Cholangiocarcinoma; Gastric Cancer; Hepatocellular Carcinoma; Merkel Cell Carcinoma; Cervical Cancer
Interventions: Drug: Continue PD-1/PD-L1 Inhibitors treatment; Other: Discontinue PD-1/PD-L1-1 inhibitor
Sponsors: Jason J. Luke, MD
Recruiting -
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors
Posted: August 6th, 2019, 11:00pm UTC
Conditions: Advanced Solid Tumors; Merkel Cell Carcinoma
Interventions: Drug: FF-10850 Topotecan Liposome Injection
Sponsors: Fujifilm Pharmaceuticals U.S.A., Inc.
Recruiting -
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Posted: May 2nd, 2019, 11:00pm UTC
Conditions: Gastric Cancer; Colorectal Cancer; Pancreatic Cancer; Sarcoma; Mesothelioma; Neuroendocrine Tumors; Squamous Cell Cancer; Merkel Cell Carcinoma; Mismatch Repair Deficiency; Microsatellite Instability
Interventions: Biological: Tumor Infiltrating Lymphocytes (TIL); Drug: Fludarabine + Cyclophosphamide combination
Sponsors: Udai Kammula
Recruiting -
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
Posted: April 3rd, 2019, 11:00pm UTC
Conditions: Melanoma; Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma
Interventions: Drug: NT-I7; Drug: atezolizumab
Sponsors: NeoImmuneTech; Immune Oncology Network
Terminated -
AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma
Posted: March 28th, 2019, 11:00pm UTC
Conditions: Malignant Glioma
Interventions: Drug: IDH1R132H peptide vaccine; Drug: Avelumab
Sponsors: German Cancer Research Center
Active, not recruiting -
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
Posted: February 25th, 2019, 1:00am UTC
Conditions: Merkel Cell Carcinoma
Interventions: Biological: Avelumab; Biological: N-803; Biological: haNKâ„¢
Sponsors: ImmunityBio, Inc.
Terminated -
Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
Posted: January 10th, 2019, 1:00am UTC
Conditions: Merkel Cell Carcinoma; Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
Interventions: Biological: Ipilimumab; Biological: Nivolumab; Radiation: Radiation Therapy
Sponsors: Claire Verschraegen
Completed -
Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
Posted: December 20th, 2018, 1:00am UTC
Conditions: Merkel Cell Carcinoma
Interventions: Drug: Pembrolizumab (MK-3475)
Sponsors: Merck Sharp & Dohme LLC
Completed -
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Posted: November 20th, 2018, 1:00am UTC
Conditions: Other Skin
Interventions: Biological: Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR; Drug: Avelumab; Biological: Pembrolizumab; Biological: Interferon Gamma-1b
Sponsors: Fred Hutchinson Cancer Center; National Cancer Institute (NCI); Affini-T Therapeutics, Inc.
Active, not recruiting -
Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial
Posted: October 19th, 2018, 11:00pm UTC
Conditions: Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8; Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8; Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions: Other: Best Practice; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Biological: Pembrolizumab; Procedure: Positron Emission Tomography; Radiation: Radiation Therapy
Sponsors: National Cancer Institute (NCI)
Active, not recruiting -
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Posted: August 14th, 2018, 11:00pm UTC
Conditions: Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck; Breast Cancer; Colorectal Cancer; Melanoma; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Merkel Cell Carcinoma; GastroEsophageal Cancer; Renal Cell Carcinoma; Castration-resistant Prostate Cancer
Interventions: Drug: Etrumadenant; Drug: Zimberelimab
Sponsors: Arcus Biosciences, Inc.
Completed -
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Posted: July 26th, 2018, 11:00pm UTC
Conditions: Metastatic Merkel Cell Carcinoma
Interventions: Drug: Retifanlimab
Sponsors: Incyte Corporation
Completed -
DOTATOC PET/CT for Imaging NET Patients
Posted: July 11th, 2018, 11:00pm UTC
Conditions: Neuroendocrine Tumors; Insulinoma; Gastrinoma; Glucagonoma; Vipoma; Pheochromocytoma; Paraganglioma; Neuroblastoma; Ganglioneuroma; Medullary Carcinoma; Pituitary Adenoma; Medulloblastoma; Merkel Cell Carcinoma; Small-cell Lung Cancer; Meningioma; Carcinoid
Interventions: Diagnostic Test: 68Ga-DOTATOC PET/CT; Diagnostic Test: 18F-FDG PET/CT
Sponsors: British Columbia Cancer Agency
Recruiting -
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
Posted: December 12th, 2017, 1:00am UTC
Conditions: Autoimmunity; Melanoma; Merkel Cell Carcinoma; Squamous Cell Carcinoma of the Skin; Basal Cell Carcinoma; Skin Cancer
Interventions: Biological: Immunotherapy
Sponsors: Washington University School of Medicine
Terminated -
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
Posted: October 9th, 2017, 11:00pm UTC
Conditions: Advanced Merkel Cell Carcinoma; Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Metastatic Merkel Cell Carcinoma; Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8; Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions: Biological: Pembrolizumab; Radiation: Stereotactic Body Radiation Therapy
Sponsors: National Cancer Institute (NCI)
Active, not recruiting -
Adjuvant Avelumab in Merkel Cell Cancer
Posted: September 5th, 2017, 11:00pm UTC
Conditions: Stage III Merkel Cell Carcinoma AJCC v8; Stage IIIB Merkel Cell Carcinoma AJCC v8; Stage IIIA Merkel Cell Carcinoma AJCC v8
Interventions: Drug: Avelumab; Other: Peripheral Blood Collection; Other: Placebo
Sponsors: University of Washington; EMD Serono
Active, not recruiting -
Phase Ib of L-NMMA and Pembrolizumab
Posted: August 2nd, 2017, 11:00pm UTC
Conditions: Non-Small Cell Lung Cancer; Malignant Melanoma; Head and Neck Squamous Cell Carcinoma; Classical Hodgkin Lymphoma; Urothelial Carcinoma Bladder; DNA Repair-Deficiency Disorders
Interventions: Drug: L-NMMA; Drug: Pembrolizumab
Sponsors: The Methodist Hospital Research Institute
Active, not recruiting -
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Posted: July 25th, 2017, 11:00pm UTC
Conditions: Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma; Head and Neck Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Renal Cell Carcinoma; Gastric Cancer; Cervical Cancer; Hepatocellular Carcinoma; Microsatellite Instability; Mismatch Repair Deficiency; Colorectal Cancer
Interventions: Drug: N-803 + Pembrolizumab; Drug: N-803 + Nivolumab; Drug: N-803 + Atezolizumab; Drug: N-803 + Avelumab; Drug: N-803 + Durvalumab; Drug: N-803 + Pembrolizumab + PD-L1 t-haNK; Drug: N-803 + Nivolumab + PD-L1 t-haNK; Drug: N-803 + Atezolizumab + PD-L1 t-haNK; Drug: N-803 + Avelumab + PD-L1 t-haNK; Drug: N-803 + Durvalumab + PD-L1 t-haNK
Sponsors: ImmunityBio, Inc.
Active, not recruiting -
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
Posted: March 8th, 2017, 1:00am UTC
Conditions: Appendix Adenocarcinoma; Human Papillomavirus-Related Anal Squamous Cell Carcinoma; Human Papillomavirus-Related Cervical Squamous Cell Carcinoma; Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis; Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma; Neuroendocrine Carcinoma; Pancreatic Neuroendocrine Tumor; Recurrent Merkel Cell Carcinoma; Recurrent Nasopharynx Carcinoma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Stage III Merkel Cell Carcinoma AJCC v7; Stage III Nasopharyngeal Carcinoma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7; Stage IV Merkel Cell Carcinoma AJCC v7; Stage IV Nasopharyngeal Carcinoma AJCC v7; Stage IV Pleural Malignant Mesothelioma AJCC v7; Stage IVA Nasopharyngeal Carcinoma AJCC v7; Stage IVB Nasopharyngeal Carcinoma AJCC v7; Stage IVC Nasopharyngeal Carcinoma AJCC v7; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions: Drug: Atezolizumab; Biological: Bevacizumab; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Active, not recruiting -
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
Posted: March 6th, 2017, 1:00am UTC
Conditions: Merkel Cell Carcinoma; Skin Cancer
Interventions: Drug: Nivolumab; Drug: Ipilimumab; Radiation: Stereotactic Body Radiation Therapy (SBRT)
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Bristol-Myers Squibb
Active, not recruiting -
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Posted: December 1st, 2016, 1:00am UTC
Conditions: Adnexal Carcinoma; Anaplastic Large Cell Lymphoma, ALK-Negative; Anaplastic Large Cell Lymphoma, ALK-Positive; Apocrine Carcinoma; Carcinoma Arising From Cylindroma; Carcinoma Arising From Spiradenoma; Digital Papillary Adenocarcinoma; Endocrine Mucin-Producing Sweat Gland Carcinoma; Extramammary Paget Disease; Extraocular Sebaceous Carcinoma; Hidradenocarcinoma; Keratoacanthoma; Malignant Sweat Gland Neoplasm; Merkel Cell Carcinoma; Microcystic Adnexal Carcinoma; NK-Cell Lymphoma, Unclassifiable; Papillary Adenocarcinoma; Porocarcinoma; Primary Cutaneous Mucinous Carcinoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Merkel Cell Carcinoma; Refractory Mycosis Fungoides; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Skin Squamous Cell Carcinoma; Refractory T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome; Signet Ring Cell Adenocarcinoma; Skin Adenoid Cystic Carcinoma; Skin Basal Cell Carcinoma; Skin Basosquamous Cell Carcinoma; Skin Squamous Cell Carcinoma; Squamoid Eccrine Ductal Carcinoma; Squamous Cell Carcinoma of Unknown Primary; Sweat Gland Carcinoma; Trichilemmal Carcinoma; Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Procedure: Positron Emission Mammography; Biological: Talimogene Laherparepvec
Sponsors: National Cancer Institute (NCI)
Active, not recruiting -
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Posted: June 30th, 2016, 11:00pm UTC
Conditions: Melanoma; Merkel Cell Carcinoma; Other Solid Tumors
Interventions: Drug: TALIMOGENE LAHERPAREPVEC (TVEC); Radiation: Hypofractionated Radiotherapy
Sponsors: Memorial Sloan Kettering Cancer Center; Amgen
Completed -
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
Posted: June 24th, 2015, 11:00pm UTC
Conditions: Acquired Immunodeficiency Syndrome; BK Virus Infection; Human Immunodeficiency Virus; JC Virus Infection; Malignant Neoplasm; Merkel Cell Carcinoma; Merkel Cell Polyomavirus Infection; Viral Encephalitis
Interventions: Biological: Allogeneic BK-specific Cytotoxic T-lymphocytes; Other: Laboratory Biomarker Analysis
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
Posted: June 15th, 2015, 11:00pm UTC
Conditions: Dermatologic Conditions; Healthy Volunteers; Normal Volunteers; Carcinoma, Merkel Cell
Sponsors: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting -
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
Posted: June 9th, 2015, 11:00pm UTC
Conditions: Stage IIIB Merkel Cell Carcinoma; Stage IV Merkel Cell Carcinoma
Interventions: Biological: aNK (NK-92); Biological: aNK (NK-92) + N-803
Sponsors: ImmunityBio, Inc.
Terminated -
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Posted: June 4th, 2014, 11:00pm UTC
Conditions: Carcinoma, Merkel Cell
Interventions: Drug: Avelumab
Sponsors: EMD Serono Research & Development Institute, Inc.
Completed -
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Posted: April 10th, 2008, 11:00pm UTC
Conditions: Gastrinoma; Glucagonoma; Insulinoma; Metastatic Gastrointestinal Carcinoid Tumor; Metastatic Pheochromocytoma; Pancreatic Polypeptide Tumor; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Melanoma; Recurrent Neuroendocrine Carcinoma of the Skin; Recurrent Non-small Cell Lung Cancer; Recurrent Pheochromocytoma; Recurrent Renal Cell Cancer; Somatostatinoma; Stage III Neuroendocrine Carcinoma of the Skin; Stage IV Melanoma; Stage IV Non-small Cell Lung Cancer; Stage IV Renal Cell Cancer; Thyroid Gland Medullary Carcinoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: everolimus; Drug: vatalanib; Other: pharmacological study; Other: laboratory biomarker analysis; Procedure: dynamic contrast-enhanced magnetic resonance imaging; Procedure: ultrasound imaging
Sponsors: Mayo Clinic
Completed